Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis).
Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis).
复制标题
DOI：
10.7497/j.issn.2095-3941.2013.03.005
复制
发表时间：
2013-09
影响因子：
5.5
通讯作者：
Lalwani S
中科院分区：
文献类型：
--
作者：
Bagaria B;Sood S;Sharma R;Lalwani S
检测50例正常人和150例食管癌、胃癌、结肠癌患者血清中癌胚抗原（CEA）和糖链抗原19-9（CA 19 -9）的浓度，并进行联合检测。单独和组合比较两种标记物的灵敏度，特异性设定为100%。绘制受试者工作特征（ROC）曲线。癌症患者的血清癌胚抗原水平明显高于对照组。测定CEA的敏感性：食管癌敏感性= 28%，阴性预测值（NPV）= 61.72%，AUC=0.742（SE=0.05），P<0.0001显著性水平;胃癌敏感性= 30%，NPV= 58.82%，AUC=0.734（SE=0.05），P<0.0001显著性水平;结肠癌敏感性= 74%，NPV= 79.36%，AUC=0.856（SE=0.04），P<0.0001显著性水平。
还评估了CA 19 -9的敏感性：在食管癌中，敏感性= 18%，NPV= 54.94%，AUC=0.573（SE =0.05），显著性水平为P=0.2054。在胃癌中，敏感性= 42%，NPV= 63.29%，AUC=0.679（SE =0.05），显著性水平为P<0.0011。在结肠癌中，灵敏度= 26%，NPV= 57.47%，AUC=0.580（SE =0.05），显著性水平为P=0.1670。CEA/CA 19 -9联合检测食管癌的敏感性为：食管癌，敏感性为42%，NPV为63.29%，SE为0.078（95%CI：0.0159-0.322）;胃癌，敏感性= 58%，NPV= 70.42%，SE=0.072结肠癌敏感性为72%，NPV为78.12%，SE为0.070（95% CI：0.137-0.415）。CEA对结肠癌的敏感性最高，CA 19 -9对胃癌的敏感性最高。联合分析表明，与结肠癌相比，食管癌和胃癌的诊断敏感性增加。
To determine the clinical serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9), individually and in combination, for the diagnosis of 50 healthy subjects and 150 cases of esophageal, gastric, and colon cancers. The sensitivities of the two markers were compared individually and in combination, with specificity set at 100%. Receiver operating characteristic (ROC) curves were plotted. Serum CEA levels were significantly higher in cancer patients than in the control group. The sensitivity of CEA was determined: in esophageal cancer, sensitivity=28%, negative predictive value (NPV)=61.72%, and AUC=0.742
(SE=0.05), with a significance level of P<0.0001; in gastric cancer, sensitivity=30%, NPV=58.82%, and AUC=0.734 (SE=0.05), with a significance level of P<0.0001; in colon cancer, sensitivity=74%, NPV=79.36%, and AUC=0.856
(SE=0.04), with a significance level of P<0.0001. The sensitivity of CA19-9 was also evaluated: in esophageal cancer, sensitivity=18%, NPV=54.94%, and AUC=0.573 (SE =0.05), with a significance level of P=0.2054. In gastric cancer, sensitivity=42%, NPV=63.29%, and AUC=0.679 (SE =0.05), with a significance level of P<0.0011. In colon cancer, sensitivity=26%, NPV=57.47%, and AUC=0.580 (SE =0.05), with a significance level of P=0.1670. The following were the sensitivities of CEA/CA19-9 combined: in esophageal cancer, sensitivity=42%, NPV=63.29%, SE=0.078 (95% CI: 0.0159-0.322); gastric cancer, sensitivity=58%, NPV=70.42%, SE=0.072 (95% CI: -0.0866-0.198); and colon cancer, sensitivity=72%, NPV=78.12%, SE=0.070 (95% CI: 0.137-0.415). CEA exhibited the highest sensitivity for colon cancer, and CA19-9 exhibited the highest sensitivity for gastric cancer. Combined analysis indicated an increase in diagnostic sensitivity in esophageal and gastric cancer compared with that in colon cancer.